欢迎来到OAJRC平台！

期刊栏目

投稿

审稿

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据：

当前位置：国际临床研究杂志 > 2023年 7卷 (3)期

Open Access Article

International Journal of Clinical Research. 2023; 7: (3) ; 34-38 ; DOI: 10.12208/j.ijcr.20230114.

Current situation and research progress of maintenance therapy for recurrent or metastasis nasopharyngeal carcinoma
复发或转移性鼻咽癌维持治疗药物应用的现状及研究进展

作者： 张艳贤 *, 陆颖, 杨慧

中国广西壮族自治区柳州市工人医院肿瘤科广西柳州

*通讯作者：张艳贤,单位：中国广西壮族自治区柳州市工人医院肿瘤科广西柳州；

发布时间: 2023-03-23 总浏览量: 248

PDF 全文下载引用本文万方数据（WANFANG DATA）

摘要

鼻咽癌是我国高发恶性肿瘤之一，鼻咽癌经放化疗后能取得较好的肿瘤控制率，但仍有约20%的患者面临复发或转移。虽然辅助化疗可能进一步降低复发和死亡风险，但其在鼻咽癌中的疗效仍存在争议。因为大部分患者经历了放化疗后身体耐受性变差，无法完成这类高强度传统化疗。因此，寻找低毒有效、耐受性好的辅助治疗策略是目前临床上迫切需要解决的一大难题。近年来众多学者开始对转移性鼻咽癌维持治疗方案进行探索研究。目前在维持药物的选择、维持治疗的时长等问题上，还存在一定争议。全文对复发或转移性鼻咽癌的维持治疗现状及目前最新进展进行综述。

关键词： 鼻咽癌；维持治疗；进展

Abstract

Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors in China. NPC can achieve a good tumor control rate after radiotherapy and chemotherapy, but about 20% of the patients still face recurrence or metastasis. Although adjuvant chemotherapy may further reduce the risk of recurrence and death, the efficacy of adjuvant chemotherapy in NPC is still controversial. Because most patients experience poor physical tolerance after radiotherapy and chemotherapy, they are unable to complete this kind of high-intensity traditional chemotherapy. Therefore, finding an effective and tolerant adjuvant therapy strategy is an urgent problem to be solved in clinic at present. In recent years, many scholars began to explore the maintenance treatment of metastatic NPC. At present, there are still some disputes on the choice of drugs and the length of treatment. In this paper, the current situation and latest progress of maintenance and treatment of recurrent or metastatic NPC were reviewed.

Key words： Nasopharyngeal Carcinoma; Maintenance Therapy; Progress

参考文献 References

[1] Chang E T, Ye W, Zeng Y X, et al. The Evolving Epidemiology of Nasopharyngeal Carcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2021,30（6）:1035-1047.

[2] Jin Y, Shi Y X, Cai X Y, et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma[J]. J Cancer Res Clin Oncol, 2012,138（10）:1717-1725.

[3] Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA: A Cancer Journal for Clinicians, 2021,71（3）:209-249.

[4] Tang L L, Chen Y P, Mao Y P, et al. Validation of the 8th Edition of the UICC/AJCC Staging System for Nasopharyngeal Carcinoma From Endemic Areas in the Intensity-Modulated Radiotherapy Era[J]. J Natl Compr Canc Netw, 2017,15（7）:913-919.

[5] Ma S X, Zhou T, Huang Y, et al. The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis[J]. Ann Transl Med, 2018,6（11）:201.

[6] 张溪夏, 曹志伟. PD-1 PD-L1单抗在复发转移性鼻咽癌中的研究进展[J]. 中国肿瘤临床, 2020,47（23）: 1231-1235.

[7] Liu G Y, Li W Z, Wang D S, et al. Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy: A Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2022,8（4）:553-561.

[8] Chen Y P, Liu X, Zhou Q, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial[J]. Lancet, 2021,398（10297）:303-313.

[9] 杨慧, 黄海欣, 吴思蓓, 等. 替吉奥维持干预在转移性鼻咽癌治疗中的时机优势研究[J]. 现代肿瘤医学, 2022,30（22）:4082-4086.

[10] Zhang H J, Yuan G L, Liang Q L, et al. Addition of bevacizumab to systemic therapy for locally advanced and metastatic nasopharyngeal carcinoma[J]. Oncol Lett, 2018,15（5）:7799-7805.

[11] Chan A T, Hsu M M, Goh B C, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma[J]. J Clin Oncol, 2005,23（15）:3568-3576.

[12] 赵舒娟, 罗利芳. 阿帕替尼单药维持治疗转移性鼻咽癌化疗后的有效性及安全性研究[J]. 中国医学文摘（耳鼻咽喉科学）, 2021,36（04）:8-9.

[13] 冯俊岭, 孔飞, 张明智. 阿帕替尼治疗复发/转移性鼻咽癌的效果[J]. 河南医学研究, 2019,28（14）:2586-2588.

[14] Koelblinger P, Emberger M, Drach M, et al. Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas[J]. J Eur Acad Dermatol Venereol, 2019,33（4）:667-675.

[15] Yarchoan M, Albacker L A, Hopkins A C, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers[J]. JCI Insight, 2019,4（6）.

[16] 彭辉, 钟碧玲, 李亦明, 等. 共刺激分子PD-L1在鼻咽癌组织中的表达和意义[J]. 热带医学杂志, 2012,12（02）:154-156.

[17] Hsu C, Lee S H, Ejadi S, et al. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study[J]. J Clin Oncol, 2017,35（36）:4050-4056.

[18] Ma B, Lim W T, Goh B C, et al. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium （NCI-9742）[J]. J Clin Oncol, 2018,36（14）:1412-1418.

[19] Wang F H, Wei X L, Feng J, et al. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial （POLARIS-02）[J]. J Clin Oncol, 2021,39（7）:704-712.

[20] Lee A, Lee V, Ng W T, et al. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma[J]. Eur J Cancer, 2021, 153: 109-122.

[21] Yang Y, Zhou T, Chen X, et al. Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma （CAPTAIN study）[J]. J Immunother Cancer, 2021,9（12）.

[22] Shen L, Guo J, Zhang Q, et al. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study[J]. J Immunother Cancer, 2020,8（1）.

引用本文

张艳贤, 陆颖, 杨慧, 复发或转移性鼻咽癌维持治疗药物应用的现状及研究进展[J]. 国际临床研究杂志, 2023; 7: (3) : 34-38.

入驻平台

回到首页

搜索文章: